Next Phase Newsletter

By Antoinette Lowre, Manager of Business Development, LSN

Digital RESI, November 15-16, 2022 is a virtual-only dedicated partnering event designed to facilitate well-fitting meetings through matching attendees based on product and stage of development. What sets Digital RESI dedicated partnering apart from the Digital RESI 3-Day events and Hybrid RESIs is the focus on virtual partnering. Digital RESI is designed to make partnering between major events simpler by connecting startups with investors and channel partners who are a fit for their product and stage of development.

Digital RESI can be optimized without travel and at a reasonable rate for busy early-stage entrepreneurs. View a tutorial of the partnering platform here! The super early bird rates end tomorrow, Friday, October 7. Early-stage startups can save $300 when they register by tomorrow!

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Last week, we organized a very successful multi-day Redefining Early Stage Investments (RESI) event, which was our first in-person event in 2+ years! At RESI Boston, we had 61 companies participate in the Innovator’s Pitch Challenge (IPC). These finalist companies pitched to a judging panel and a full audience and exhibited a poster showcasing their technology. All attendees were provided with “RESI Cash” to vote for their favorite innovators.

RESI Boston 2022 Innovator’s Pitch Challenge Winners

1^st Place – Suma

Denice Wharton, Founder/CEO of Suma

Suma is an online management system that simplifies and streamlines the licensing and renewal process for medical professionals. Initially, our product will target workers that have an increased labor market dropout risk yet are in high demand, highly diverse and have high care impact. Certified Nurse Assistants (CNA) and Home Health Aides (HHA) provide basic direct patient care, measure vitals and help patients with activities of daily living (ADL) such as feeding, grooming, bathing, etc. They work predominantly in nursing homes, home health agencies, hospitals, and other long-term care settings caring for the elderly, sick and/or disabled. These positions are held mostly by people of color, women, immigrants, low income and at-risk populations, and are considered entry-level nursing positions. There is an overwhelming need for these healthcare workers nationwide and creating an easy way to maintain their employment will provide resources for our economy and save businesses thousands of dollars every year.

2^nd Place – Leuko Labs

Carlos Castro Gonzalez, CEO of Leuko Labs

Leuko is an MIT spinout developing PointCheckTM, the world’s first medical device that can monitor white blood cells non-invasively. By enabling more frequent at-home monitoring, Leuko aims to improve clinical outcomes for more than 2M cancer chemotherapy patients a year, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost.

3^rd Place – RudaCure

Yong Ho Kim, CEO of RUDACURE

RudaCure is a clinical stage bio-pharmaceutical start-up founded in 2018 and based in South Korea that is developing medicines for incurable diseases based on the most advanced life-science technologies to help improve human lives. By developing treatment techniques for intractable and incurable diseases, RudaCure will solve its unmet needs and treat the physical and mental pain for patients suffering from them. With creative pharmaceutical development and biomedical research, RudaCure is on the path to grow into a global pharmaceutical company.

Current main products in development include RCI001 for dry eye disease, which is in pre-IND phase and awaiting to start Phase 2 FDA clinical trials next year. RudaCure also plan to secure additional indications for RCI001 including conjunctivitis, keratitis and corneal ulcers. Second in development is RCI002, which is a non-opioid treatment for neuropathic and chronic pain currently in optimization stage. Other early stage products in development include treatments for atopic dermatitis, metastasis and CRPS.

Since April of 2021, RudaCure has successfully licensed-out RCI001 to Hanlim Pharm for domestic rights in a $12 million deal, and is currently looking for more investors and partners to license-out for international markets. Helping RudaCure along the way, are start-up accelerators MassChallenge and Shinhan Square Bridge, which are both helping RudaCure enter the US market.

By Alexander Vassallo, Manager of Business Development West Coast (US), Entrepreneurial Education Lead, LSN

With over 2,700 early-stage fundraising executives, active investors, strategic partners, and licensing collaborators having attended RESI events in 2022, Life Science Nation (LSN) is proud to announce the opening of our final partnering event for the year – Digital RESI November. Over the course of two days of dedicated virtual partnering November 15-16, Digital RESI November will serve as an exciting platform for innovative technology assets to be met with active capital and professional services.

The format for Digital RESI November will differ slightly from previous editions of the partnering conference. The two days will be purely dedicated to partnering, as the Innovator’s Pitch Challenge (IPC) and our industry-standard panels, workshops, and content will rejoin RESI in January, 2023 as RESI heads to San Francisco for JPM week. All attendees will have access to 96 30-minute slots during the two-day partnering conference with which they can continue the conversation with existing partners and establish the dialogue with new ones.

As LSN once again welcomes life science startups (across the domains of therapeutics, medical devices, diagnostics, and digital health) looking for capital and partners, active investors looking for novel technology assets, and strategic partners looking for exciting companies to add to their portfolio to the RESI platform this November, we would also like to take the time to thank the 2,700+ attendees who have previously attended RESI this year. We are proud to have facilitated the growth of the global early-stage life science sector and look forward to seeing you all virtually for the final partnering event of 2022.

SAVE $300 on Super Early Bird Rates by Friday, October 7.